Madri­gal re­ports new safe­ty da­ta for NASH can­di­date resme­tirom weeks ahead of PDU­FA date

Madri­gal has lift­ed the cur­tain on ad­di­tion­al late-stage safe­ty re­sults for its non­al­co­holic steato­hep­ati­tis (NASH) drug resme­tirom, with an­a­lysts ex­press­ing over­all op­ti­mism on the loom­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER